Clinical Trials Browser

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Myofibromatosis, Carcinoma, Medullary

NCT01196936 2026-01-05

LDTam

Phase 2 Active not recruiting

84 enrolled 17 charts

Breast

Breast Neoplasms

NCT02115282 2025-12-18

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Phase 3 Active not recruiting

608 enrolled 18 charts

Breast

Breast Neoplasms

NCT04905082 2025-12-11

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

Phase NA Active not recruiting

465 enrolled 11 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Phase 2 Active not recruiting

84 enrolled 17 charts

Breast

Breast Neoplasms

NCT03483012 2025-12-09

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Phase 2 Active not recruiting

6 enrolled 19 charts

Breast

Breast Neoplasms

NCT02263014 2025-11-26

Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM)

Active not recruiting

345 enrolled 9 charts

Breast

Breast Neoplasms

NCT01750073 2025-11-18

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Phase 2 Active not recruiting

92 enrolled 17 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04425018 2025-11-18

MARGOT

Phase 2 Active not recruiting

174 enrolled 19 charts

Breast

Breast Neoplasms

NCT01093612 2025-11-14

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Phase NA Active not recruiting

18 enrolled 6 charts

Breast

Breast Neoplasms

NCT02293954 2025-11-14

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Phase NA Active not recruiting

20 enrolled 8 charts

BreastGastrointestinalThoracic

Bile Duct Neoplasms, Breast Neoplasms, Colonic Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Rectal Neoplasms, Carcinoma, Medullary

NCT02827877 2025-11-14

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Phase 2 Active not recruiting

18 enrolled 8 charts

Breast

Breast Neoplasms

NCT03218826 2025-10-30

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Active not recruiting

23 enrolled 15 charts

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

CONFIRM

TAILORx

VERITAC-2

Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer

INAVO120

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

CARABELA

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

FELINE

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

DB-06

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

MRI-Based Preoperative Accelerated Partial Breast Irradiation

OlympiA

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making

DESTINY-B12

e3

Next MONARCH 1

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

MONARCH plus

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

MONARCH 3

PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions

BEGONIA

MEDIOLA

SHE-WOMEN

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

postMONARCH

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

MK-7119-001

LIBRETTO-121

LDTam

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM)

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

MARGOT

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery